logo
Plus   Neg
Share
Email

Heron Gets CRL For HTX-011 For Management Of Postoperative Pain; Stock Down

Heron Therapeutics Inc. (HRTX) said that it received a Complete Response Letter or CRL from the U.S. Food and Drug Administration regarding its New Drug Application for HTX-011 for the management of postoperative pain.

In Monday pre-market trade, HRTX is trading at $17.55, down $2.27 or 11.45 percent.

The Complete Response Letter has requested additional non-clinical information. The FDA did not identify any clinical safety or efficacy issues or CMC issues, the company said in a statement.

There are four non-clinical issues in the CRL, none of which relate to any observed toxicity, the company said. Three relate to confirming exposure of excipients in preclinical reproductive toxicology studies, and the fourth relates to changing the manufacturing release specification of the allowable level of an impurity based on animal toxicology coverage.

The company noted that it will request a Type A meeting to obtain agreement with the Agency on its responses and resubmit the application as quickly as possible.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Department of Health and Human Services or HHS said it has secured most of the supply of COVID-19 drug remdesivir through September. The deal would allow American hospitals to purchase the antiviral drug in allocated amounts amid the spike in confirmed cases each day. HHS Secretary Alex Azar said, "President Trump has struck an amazing deal to ensure Americans have access to the first..." Novartis AG (NVS) agreed to pay $678 million to settle U.S. government charges it paid illegal kickbacks to doctors to induce them to prescribe its cardiovascular and diabetes drugs, the U.S. Department of Justice said in a statement. PG&E Corp. (PCG) said Wednesday that it has emerged from Chapter 11 bankruptcy protection, after implementing its financial restructuring plan that was previously approved by the U.S. Bankruptcy Court and state regulators.
RELATED NEWS
Follow RTT